The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Dobson, Rebecca ^a,b   Burgess, Malcolm I ^a   Banks, Melissa ^a   Pritchard, D Mark ^b,c   Vora, Jiten ^c   Valle, Juan W ^d   Wong, Christopher ^a   Chadwick, Carrie ^a   George, Keith ^e   Keevil, Brian ^f   Adaway, Joanne ^f   Ardill, Joy E S ^g   Anthoney, Alan ^h   Hofmann, Uschi ⁱ   Poston, Graeme J ^a   Cuthbertson, Daniel J ^a,b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^f MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL VICTORIA HOSPITAL   (United Kingdom)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CHROMOGRANIN A; CHROMOGRANIN B; NEUROKININ A; TUMOR MARKER;

AGED; ARTICLE; CARCINOID SYNDROME; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; BIOLOGICAL MARKERS; CARCINOID HEART DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; NEUROKININ A;

EID: 84884196957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073679     Document Type: Article

References (29)

1. Howard RJ, Drobac M, Rider WD, Keane TJ, Finlayson J, et al. (1982) Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 66: 1059-1065.
2. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J, (2009) Drug-induced fibrotic valvular heart disease. Lancet 374: 577-585.
3. Jackson LN, Chen LA, Larson SD, Silva SR, Rychahou PG, et al. (2009) Development and characterization of a novel in vivo model of carcinoid syndrome. Clinical Cancer Research 15: 2747-2755.
4. Bergestuen DS, Edvardsen T, Aakhus S, Ueland T, Oie E, et al. (2010) Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis. Neuroendocrinology 92(3): 168-77.
5. Bergestuen D, Gravning J, Haugaa K, Sahakyan LG, Aakhus S, et al. (2010) Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. BMC Cancer 10: 6.
6. Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, et al. (2010) Features of Carcinoid Heart Disease Identified by 2- and 3- Dimensional Echocardiography and Cardiac MRI. Circ Cardiovasc Imaging 3: 103-111.
7. Lillegard JB, Fisher JE, Mckenzie TJ, Que FJ, Farnell MB, et al. (2011) Hepatic Resection for the Carcinoid Syndrome in Patients with Severe Carcinoid Heart Disease: Does Valve Replacement Permit Safe Hepatic Resection? J Am Coll Surg 213: 130-138.
8. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, et al. (2003) Factors Associated with Progression of Carcinoid Heart Disease. N Engl J Med 348: 1005-1015.
9. Plockinger U, Gustafsson BI, Ivan D, Szpak W, Davar J, (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Echocardiography. Neuroendocrinology 90: 190-193.
10. Korse KM, Taal BF, de Groot CA, Bakker RH, Bonfrer JMG, (2009) Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumour. J Clin Oncol 27: 4293-4299.
11. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BF, (2004) Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 90: 2073-2079.
12. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J, (2008) Usefulness of N-terminal Pro-Brain Natriuretic Peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol 102: 938-942.
13. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RGP, (2006) Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 55: 1586-1591.
14. Zuetenhorst JM, Bonfrer JMG, Korse CM, Bakker RH, van Tinteren H, et al. (2003) Carcinoid heart disease. Cancer 97: 1609-1615.
15. Denney W, Kemp WE, Anthony LB, Oates JA, Byrd BF, (1998) Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 32: 1017-1022.
16. Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meeran KM, et al. (2012) Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol 76; 831-836.
17. Sekiya K, Ghatei MA, Sajahuddin MJ, Bishop AE, Hamid QA, et al. (1989) Production of GAWK (Chromogranin-B 420-493)-like Immunoreactivity by Endocrine Tumours and Its Possible Diagnostic Value. J Clin Invest 83: 1834-1842.
18. Hess G, Runkel S, Zdunek D, Hitzler W, (2005) Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP):A study in blood donors. Clin Chim Acta 360: 187-193.
19. Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA, (2012) A Single Fasting Plasma 5HIAA Value Correlates With 21-Hour Urinary 5HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumours (NETs). Pancreas 42: 45-410.
20. Miller AG, Brown H, Degg T, Allen K, Keevil BG, (2010) Measurement of plasma 5-hydroxyindole acetic acid by liquid chromatography tandem mass spectrometry- Comparison with HPLC methodology. J Chromatogr B 878: 695-699.
21. Mamikunian P, Ardill JE, O'Dorisio TM, Krutzig SR, Vinik AI, et al. (2011) Validation of Neurokinin A Assays in the United States and Europe. Pancreas 40: 1000-1005.
22. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, et al. (2006) ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in Collaboration With the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114: e84-e231.
23. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, et al. (2010) Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. J Am Soc Echocardiogr 23: 685-713.
24. Pape UF, Perren A, Niederle B, Gross D, Gress T, et al. (2012) ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas. Neuroendocrinology 95: 135-156.
25. Vinik A, Woltering EA, Warner RRP, Caplin M, O'Dorisio TM, et al. (2010) NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumour. Pancreas 39: 6; 713-734.
26. Mosli HH, Dennis A, Kocha W, Asher L, Van Uum SHM, (2012) Effect of Short-Term Proton Pump Inhibitor Treatment And Its Discontinuation On Chromogranin A in Healthy Subjects. J Clin Endocrinol Metab 97: E1731-E1735.
27. Korse CM, Muller M, Taal BG, (2011) Discontinuation Of Proton Pump Inhibitors During Assessment of Chromogranin A Levels In Patients With Neuroendocrine Tumours. Br J Cancer 105: 1173-1175.
28. Heidrich FM, Zhang K, Estrada M, Huang Y, Giordano FJ, et al. (2008) Chromogranin B Regulates Calcium Signaling, Nuclear Factor κB Activity, and Brain Natriuretic Peptide Production in Cardiomyocytes. Circ Res 102: 1230-1238.
29. Stridsberg M, Eriksson B, Fellstrom B, Kristiansson G, Janson ET, (2007) Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept. 139: 80-83.